EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ampio Pharmaceuticals's enterprise value is $-3.53 Mil.
Ampio Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Ampio Pharmaceuticals's EV-to-Revenue for today is .
The historical rank and industry rank for Ampio Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Ampio Pharmaceuticals was 5451.55. The lowest was -99999999.99. And the median was -4.51.
AMPE's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.18 * Ranked among companies with meaningful EV-to-Revenue only.
Ampio Pharmaceuticals EV-to-Revenue Historical Data
The historical data trend for Ampio Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ampio Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, Ampio Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ampio Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ampio Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ampio Pharmaceuticals's EV-to-Revenue falls into.
Ampio Pharmaceuticals's current Enterprise Value is $-3.53 Mil.
Ampio Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ampio Pharmaceuticals's share price for today is $0.25.
Ampio Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ampio Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Ampio Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ampio Pharmaceuticals (Ampio Pharmaceuticals) Business Description
Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the clinical development of Ampion and preclinical development. Its product candidate, Ampion, is in clinical trials and is being developed for the treatment of severe Osteoarthritis of the Knee, an intravenous treatment for COVID-19 patients, and an inhaled treatment for COVID-19-induced respiratory distress.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMPE has been successfully added to your 